Article
Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
Molecular diagnosis & therapy - 1 Feb 2020
Selvam Pavalan, Hsiao Meng-Chang, Omerza Gregory, Bergeron Daniel, Rowe Shannon, Uvalic Jasmina, Soucy Melissa, Peracchio Michael, Burns Shelbi, Meyers Bridgette, Prego Matthew, Nie Qian, Ananda Guruprasad, Chandok Harshpreet, Kelly Kevin, Hesse Andrew, Reddi Honey V
Abstract excerpt
OBJECTIVE: The study aimed to retrospectively evaluate the positive yield rate of a custom 212-gene next-generation sequencing (NGS) panel, the JAX ActionSeq™ assay, used in molecular profiling of solid tumors for precision medicine. METHODS: We evaluated 261 cases tested over a 24-month period including cancers across 24 primary tissue types and report on the mutation yield in these cases. RESULTS: Thirty-three...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.